Stocklytics Platform
Asset logo for symbol INMB
Inmune Bio
INMB43
$5.11arrow_drop_down2.10%-$0.11
Asset logo for symbol INMB
INMB43

$5.11

arrow_drop_down2.10%

Performance History

Chart placeholder
Key Stats
Open$5.32
Prev. Close$5.22
EPS-2.05
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$103.51M
PE Ratio-
LOWHIGH
Day Range5.07
5.40
52 Week Range5.07
14.74
Ratios
Revenue-
EBITDA Margin %-
EPS-2.05

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Inmune Bio (INMB)

Inmune Bio Inc (INMB) is a biopharmaceutical company focused on developing products for the treatment of cancer and neuroinflammatory diseases. The company's lead product candidate, INB03, is a potential treatment for Alzheimer's disease. This innovative drug works by targeting a protein called CD33, which is believed to play a role in the development of Alzheimer's. In preclinical studies, INB03 has shown promise in reducing neuroinflammation and restoring cognitive function.
In addition to its work in Alzheimer's, Inmune Bio is also developing INKmune, a treatment for resistant cancers. This therapy utilizes the body's own immune system to target and kill cancer cells. By harnessing the power of the immune system, INKmune has the potential to be a highly effective and less toxic alternative to traditional cancer treatments.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Raymond Joseph Tesi M.D.
Headquarters
Boca Raton
Employees
10
Exchange
NASDAQ
add Inmune Bio  to watchlist

Keep an eye on Inmune Bio

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Inmune Bio 's (INMB) price per share?

The current price per share for Inmune Bio (INMB) is $5.11. The stock has seen a price change of -$0.11 recently, indicating a -2.11% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Inmune Bio (INMB)?

For Inmune Bio (INMB), the 52-week high is $14.74, which is 188.45% from the current price. The 52-week low is $5.07, the current price is 0.79% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Inmune Bio (INMB) a growth stock?

Inmune Bio (INMB) has shown an average price growth of 0.41% over the past three years. It has received a score of 58 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Inmune Bio as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Inmune Bio (INMB) stock price performance year to date (YTD)?

As of the latest data, Inmune Bio (INMB) has a year-to-date price change of -54.46%. Over the past month, the stock has experienced a price change of -20.78%. Over the last three months, the change has been -32.14%. Over the past six months, the figure is -58.11%. Looking at a longer horizon, the five-year price change stands at -7.93%.
help

Is Inmune Bio (INMB) a profitable company?

Inmune Bio (INMB) has a net income of -$30.01M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -44.46K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $155K. Operating income is noted at -$29.74M. Furthermore, the EBITDA is $0.
help

What is the market capitalization of Inmune Bio (INMB)?

Inmune Bio (INMB) has a market capitalization of $103.52M. The average daily trading volume is 399.69K, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media